Maksafibroosin

Maksafibroosin is a synthetic, non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It is a derivative of the drug ibuprofen, with the addition of a methyl group to the 4-position of the phenyl ring. This modification increases its lipophilicity, allowing it to cross the blood-brain barrier more easily than ibuprofen. This property makes maksafibroosin effective in treating conditions such as migraines and cluster headaches, where pain is often localized to the head.

Maksafibroosin is available in various forms, including tablets, capsules, and oral suspensions. It is typically taken orally, with or without food, depending on the specific formulation and the patient's preference. The drug is generally well-tolerated, but like other NSAIDs, it can cause side effects such as gastrointestinal upset, including nausea, vomiting, and stomach pain. It can also increase the risk of bleeding and ulcers in the stomach and intestines.

Maksafibroosin is not recommended for use in patients with a history of stomach ulcers or bleeding disorders, or those who are allergic to NSAIDs. It should also be used with caution in patients with kidney or liver disease, as these conditions can affect the drug's metabolism and elimination. Pregnant and breastfeeding women should consult their healthcare provider before using maksafibroosin, as its safety in these populations has not been fully established.